- •Preface
- •Contents
- •Contributors
- •1 Introduction
- •1.1 Historical Background
- •1.2 Pitfalls in Diagnosis and Methodology
- •1.3 Methods to Assess Disease Activity
- •1.4 Summary
- •References
- •2.1 Introduction
- •2.4 Pearls of Wisdom
- •References
- •3.1 Background: Overall Approach to Patient Care
- •3.1.1 Pearl
- •3.1.2 Pearl
- •3.2 Diagnosis Criteria and Laboratory Tests
- •3.2.1 Myth
- •3.2.2 Pearl
- •3.2.3 Myth
- •3.2.4 Myth
- •3.2.5 Pearl
- •3.2.6 Pearl
- •3.2.7 Pearl
- •3.3 Myths and Pearls About Clinical Presentations
- •3.3.1 Pearl
- •3.3.2 Myth
- •3.3.3 Pearl
- •3.3.4 Pearl
- •3.3.5 Pearl
- •3.3.6 Pearl
- •3.3.7 Pearl
- •3.3.8 Pearl
- •3.3.9 Pearl
- •3.3.10 Pearl
- •3.3.11 Pearl
- •3.3.12 Pearl
- •3.3.13 Myth
- •3.3.14 Pearl
- •3.3.15 Pearl
- •3.3.16 Myth
- •3.4 Myths and Pearls About Pathogenesis
- •3.4.1 Myth
- •3.4.2 Pearl
- •3.4.3 Pearl
- •3.4.4 Myth
- •3.4.5 Pearl
- •3.5 Myths and Pearls About Treatment
- •3.5.1 Myth
- •3.5.2 Pearl
- •3.5.3 Pearl
- •3.5.4 Pearl
- •3.5.5 Pearl
- •3.5.6 Pearl
- •3.5.7 Pearl
- •References
- •4.1 Background and Overview
- •4.1.1 Need for Written Information
- •4.1.2 Use of Internet as a Method to Provide Information
- •4.1.3 Patient Access to Computers
- •4.1.4 Types of Information Supplied to Patients and Referring Physicians
- •4.2.1 Background: The Confusion Surrounding Criteria for Autoimmune Disorders
- •4.2.5 Criteria for Fibromyalgia
- •4.3 Laboratory Results for ANA Often Drive Clinical Diagnosis
- •4.5 Status of Biologic Drugs in SS Patients
- •4.6 Ocular Treatment
- •4.6.2 Blepharitis
- •4.7 Therapy of Oral Manifestations
- •4.7.1 Prevention of Dental Caries
- •4.7.2 Oral Candida Prevention and Treatment
- •4.8 Summary
- •References
- •5.1 Introduction
- •5.4 Outcome Measures in SS
- •5.4.1 Outcome Measures in SS: A Brief History
- •5.6 Outcome Measures in SS: The Italian Study
- •References
- •6.1 Introduction
- •6.2 Benign Lymphoepithelial Lesion in Salivary Glands
- •6.3.1.2 Ectopic Germinal Center Formation
- •6.3.1.3 Clinical Implications of Ectopic Germinal Center Formation
- •6.4 Late Breaking Update
- •References
- •7.1 Conventional Radiographs
- •7.1.1 Sialography
- •7.2 Computer Tomography
- •7.3 Ultrasound
- •7.4 Magnetic Resonance Imaging
- •7.5 Nuclear Medicine
- •7.5.1 Scintigraphy
- •7.6 Comparison of Nuclear Medicine, Ultrasound, and MRI
- •References
- •8.1 Introduction
- •8.2 Evidence Supporting a Genetic Component in SS
- •8.4 Lessons from SLE and Other Autoimmune Diseases
- •8.5 Genes Implicated in SS
- •8.7 Insights from Genomic and Proteomic Studies
- •8.8 Conclusion
- •References
- •9.1 Introduction
- •9.2.4 Antibodies to Nuclear Protein NA14
- •9.3.1 Initiation Phase
- •9.3.2 Recognition Phase
- •9.3.3 Establishment Phase: Autoreactive T and B Lymphocytes Dysregulation and Aberrant Cytokines Production
- •9.3.5 Effector Phase
- •References
- •10.1 Introduction
- •10.2.1 Ro/La RNP Particles
- •10.2.3 The Ro60 Autoantigen
- •10.2.4 The Ro52 Autoantigen
- •10.2.5 The Multifunctional Chaperone Calreticulin
- •10.4.2 Early Epitope Recognition in Autoimmune Diseases and Epitope Spreading
- •References
- •11.2 Acinar Cell
- •11.3 Neuropeptides
- •11.3.1 Acinotrophic Neurogenic Stimuli
- •11.4 Sex Steroids
- •11.4.1 Steroidogenesis in Adrenal Glands
- •11.4.2 Regulation of the Adrenal Steroidogenesis
- •11.4.4 Peripheral Intracrine Synthesis of Sex Steroids
- •11.4.5 Intracrine Sex Steroids Production in pSS and sSS
- •11.4.7 Putative Mechanism of Action of the Intracrine Processing Defect
- •11.5.1 General Histopathology
- •11.5.2 T Lymphocytes
- •11.5.3 B Lymphocytes
- •11.5.4 Chemokines
- •11.5.5 Adhesion Molecules
- •11.5.6 Cytokines
- •References
- •12.1 Background
- •12.2 Incidence, Symptomatic Presentation, and Impact on Quality of Life
- •12.3 Diagnostic Screening Examination
- •12.4 Overview of Dry Eye Management
- •12.4.1 Dry Eyes Deserve Respect and Careful Monitoring
- •12.4.2 Four Levels of Severity Differentiation
- •12.4.2.1 Level 1
- •12.4.2.2 Level 2
- •12.4.2.3 Level 3
- •12.4.2.4 Level 4
- •12.5.2 General Guidelines for the Dry Eye Patient
- •12.6 Additional Types of Therapy
- •12.7 Moisture Preservation and Oral Medications
- •12.7.2 Punctal Plugs
- •12.8 Oral Medications and Supplements
- •12.8.1 Dietary Fatty acids (Flaxseed Oil) and Dry Eyes
- •12.8.2 Oral Medications
- •12.9 Complications Associated with Ophthalmologic Cosmetic Procedures
- •12.10 Summary
- •References
- •13.1 Introduction
- •13.2 The Lacrimal Functional Unit (LFU)
- •13.3 The General Role of the LFU in Normal and Pathological Situation
- •13.4 Innervation of the Lacrimal Functional Unit
- •13.5 Efferent Structures
- •13.5.1 Lacrimal Glands
- •13.5.2 Goblet Cells
- •13.5.3 Meibomian Glands
- •13.6 Maintenance of the Lacrimal Functional Unit
- •13.6.1 Hormonal
- •13.6.2 Immunological
- •13.8 The Normal Ocular Surface Environment
- •13.9 The Makeup of the Tear Film
- •13.9.1 Hydrated Mucin Gel
- •13.9.3 Aqueous Components
- •13.10 The Pathophysiology of Dry Eye
- •13.10.1 Loss of Hormonal Support
- •13.10.2.1 Afferent Arm
- •13.10.2.2 Efferent Arm
- •13.11 Loss of Ocular Surface Homeostasis
- •13.11.1 Alterations of the Mucin, Lipid, and Aqueous Composition
- •13.11.2 Mucins
- •13.11.3 Lipids
- •13.12 The Ocular Surface Immunosuppressive Environment
- •13.14 Late-Breaking Additions
- •References
- •14.1 Saliva in Oral Health and Disease
- •14.1.1 Saliva in Dental and Mucosal Defense
- •14.1.2 Assessment of Oral Dryness
- •14.1.2.2 Objective Measurements of Hyposalivation
- •14.2 Saliva as a Diagnostic Fluid
- •14.2.1 Biomarker Analyses in Saliva
- •14.3 Complications of Oral Dryness
- •14.3.1 Management of Xerostomia
- •14.3.2 Caries Preventive Measures
- •14.3.2.3 Dietary Advice
- •14.3.2.4 The Time Factor
- •References
- •15.1.1 Endothelial Cells
- •15.1.2 Epithelial Cells
- •15.1.3 T cells
- •15.1.4 B cells
- •15.2 Mechanisms Mediating Salivary Gland Dysfunction
- •15.2.1 Acinar Cell Innervation and Humoral Immunity
- •15.2.3 Fluid Movement in the Salivary Glands and Aquaporins
- •15.3.1 Environmental Factors
- •15.3.2 Secondary Signals
- •15.3.3 Apoptosis, Autoantigens, and Potential Danger Signals in the Salivary Glands
- •15.3.4 Immunoregulation
- •15.3.5 B-cell-Activating Factor
- •15.3.6 Hormones
- •15.3.7 Microchimerism
- •References
- •16.1 Introduction
- •16.2 Diagnosis
- •16.3 Head and Neck Manifestations
- •16.3.1 Ophthalmic
- •16.3.2 Oral
- •16.3.3 Otologic
- •16.3.4 Rhinologic
- •16.3.5 Laryngeal
- •16.3.6 Esophageal
- •16.3.7 Thyroid
- •16.3.8 Neurological
- •16.4 Treatment
- •16.5 Conclusion
- •16.6 Patient Handout
- •References
- •17.1 Introduction
- •17.2 Cutaneous/Dermatologic Manifestations
- •17.4 Endocrinopathic/Pancreatic Manifestations
- •17.4.1 Hypothyroidism
- •17.4.2 Adrenal
- •17.4.3 Pancreas
- •17.5 Pulmonary Manifestations
- •17.5.1 Interstitial Pneumonitis
- •17.6.1 Pericarditis
- •17.6.2 Autonomic Manifestations
- •17.6.3 Congenital Heart Block
- •17.6.4 Accelerated Atherosclerosis
- •17.7 Gastrointestinal Manifestations
- •17.8 Hepatic and Pancreatic Manifestations
- •17.9 Renal/Urological Manifestations
- •17.10 Hematologic Manifestations
- •17.11 Obstetrical/Gynecological Manifestations
- •17.12 Vasculitis
- •17.12.1 CNS Arteritis in the SS Patient
- •17.13 Differential Diagnosis of Extraglandular Manifestations of SS
- •17.13.1 Medications and Other Metabolic Disorders
- •17.14 Manifestations and Differential Diagnosis in the Pediatric Population
- •17.15 Summary
- •17.16 Late-Breaking Updates
- •References
- •18.1 Introduction
- •18.2 Treatment and Management of Cutaneous Manifestations
- •18.2.1 Treatment of Dry Skin
- •18.3 Arthralgia/Arthritis
- •18.4.1 Chronic Cough
- •18.5 Renal Manifestations
- •18.5.1 Interstitial Nephritis
- •18.5.1.1 Glomerular Disease
- •18.6 Gastrointestinal Manifestations
- •18.6.1 Mesenteric Vasculitis
- •18.6.2 Primary Biliary Cirrhosis
- •18.7 Urologic
- •18.8 Therapeutic Management of Obstetrical/Gynecological Manifestations
- •18.9 Special Precautions at the Time of Surgery
- •18.10 Vaccinations in the SS Patient
- •18.11 Summary
- •18.12 Late-Breaking Updates
- •References
- •19.1 Introduction
- •19.3.1 Fatigue
- •19.3.2 Musculoskeletal
- •19.3.4 Gastrointestinal Manifestations
- •19.3.5 Liver Involvement
- •19.3.6 Lung Involvement
- •19.3.7 Kidney Involvement
- •19.3.8 Neurologic Involvement
- •19.3.9 Hematologic Involvement
- •19.4 Conclusions
- •References
- •20.1 Introduction
- •20.2 Diagnosis
- •20.3 Staging and Evaluation of Treatment Response
- •20.4 Treatment
- •20.5 Summary/Pearls
- •References
- •21.1 Introduction
- •21.2 What Is Fatigue?
- •21.3 Potential Causes of Fatigue in pSS
- •21.3.1 Biological
- •21.3.1.1 Cytokines
- •21.3.1.2 Neuroendocrine
- •21.3.1.3 Sleep
- •21.3.2 Psychosocial
- •21.3.2.1 Depression
- •21.3.2.2 Fibromyalgia
- •21.4 Measurement of Fatigue and Other Extraglandular Symptoms
- •21.6 Potential Approaches to Treatment of Fatigue and Other Extraglandular Symptoms
- •21.7 Measurement of Dryness (Sicca) Symptoms
- •21.8 Data from Existing Clinical Studies Addressing Dryness in pSS
- •21.9 Conclusion: Clinical Trial Outcomes
- •References
- •22.1 Introduction
- •22.2 Clinical Evaluation of Neurological Findings in SS
- •22.3.1 Role of Cell-Mediated Immunity
- •22.3.2 The Role of Antibodies Associated with Neurological Manifestations of SS
- •22.4 Investigations
- •22.4.1 Neurophysiology
- •22.4.2 Autonomic Studies
- •22.4.3 MR Imaging of the Spinal Cord
- •22.5 Peripheral Clinical Manifestations
- •22.6 Painful Sensory Neuropathies
- •22.6.1 Differential Diagnosis
- •22.7 Sensory Ataxic Neuropathy
- •22.7.1 Differential Diagnosis
- •22.8 Neuromuscular Weakness
- •22.8.1 Differential Diagnosis
- •22.9 Neuromuscular Pain
- •22.9.1 Differential Diagnosis
- •22.10 Autonomic Neuropathy
- •22.10.1 Differential Diagnosis
- •22.11 Trigeminal Neuropathy and Other Cranial Neuropathies
- •22.12 Central Nervous System Manifestations
- •22.12.2 Cognitive Impairment
- •22.12.3 Movement Disorders
- •22.12.4 Aseptic meningitis and Meningoencephalitis
- •22.12.5 Other Neurological Disorders
- •22.13 Investigations of Central Nervous System Manifestations
- •22.13.1 Serology
- •22.13.2 Spinal Fluid
- •22.13.4 Nuclear Brain Imaging Studies
- •22.13.5 Cerebral Angiography
- •22.14 The Puzzling Neurological Manifestations of Fibromyalgia
- •22.15 Interpretation of ANA in the Patient with Neurological Symptoms
- •22.16 Treatment
- •22.16.1 Peripheral Nervous System Treatment: Overview
- •22.16.2 Painful Sensory Neuropathies
- •22.16.3 Ataxic Neuropathy
- •22.16.4 Motor and Sensory Neuropathies
- •22.16.5 Central Nervous System Treatment
- •22.16.6 Side Effects of Immunosuppressive Therapy
- •22.17 Summary of Special Points to Neurologists
- •22.17.3 Relationship of Neurological Symptoms to Sicca Manifestations
- •22.18 Summary for Rheumatologists
- •References
- •23.1 Introduction
- •23.3.1 Labial Minor Salivary Gland Biopsy
- •23.3.2 Sialography
- •23.4 The Application of a Bite Guard
- •References
- •24.1 Introduction
- •24.2 How to Provide the Essential Tear Components to the Ocular Surface
- •24.3 Use of Autologous Serum Eye Drops for the Treatment of Dry Eye
- •24.4 Ongoing Research with Autologous Serum Eye Drops
- •24.5 Preparation of Autologous Serum Eye Drops
- •24.8 Conclusion
- •References
- •References
- •27.1 A Disease of Antiquity in Ancient China
- •References
- •References
- •References
- •30.1 Introduction
- •30.2 Evaluation of Systemic Features of Primary SS
- •30.2.4 Comparisons of Systemic Disease Activity Scores
- •30.3.1 The SSI: Sicca Symptoms Inventory
- •30.4 Conclusion
- •References
- •31.1 Clinical Practice Guidelines
- •31.2 Clinical Trials Consortium
- •31.3 Professional Education and Awareness
- •31.4.1 Rheumatology Working Group
- •31.4.2 Ocular Working Group
- •31.4.3 Oral Working Group
- •31.4.5 Facilitator for Both Initiatives
- •32.1 Introduction
- •32.2 For Which Patients Should Biological Therapy Be Considered?
- •32.7 BAFF Inhibition
- •32.8 Interferon Inhibition
- •32.9 Gene Therapy
- •32.10 Other Targets for Biologic Therapy
- •32.11 Conclusions and Future Directions
- •References
- •33.1 Overview of the Pathogenesis of pSS
- •33.1.1 Initial Steps
- •33.1.1.1 Breach of Self-tolerance
- •33.1.1.2 Activation of Innate Immunity and Interferon Pathways
- •33.1.1.4 Regulation of BAFF Secretion
- •33.1.1.6 Other Cytokines, Chemokines, and Adhesion Molecules Are Involved in the Pathogenesis of the Disease
- •33.1.3 Glandular Hypofunction Rather Than Glandular Destruction
- •33.2 Emerging Therapies
- •33.2.1 Prerequisite for the Development of New Drugs in pSS
- •33.2.1.1 Disease Activity Score
- •33.2.1.2 Selection of Patients
- •33.2.3.1 Inhibition of the Triggering Factors of IFN Activation
- •33.2.3.2 IFN Blockade
- •33.2.3.3 Antagonists of BAFF and APRIL
- •33.2.3.4 B-cell Depletion
- •33.2.3.5 Other B-cell-Targeted Therapy: Other Anti-CD20 and Anti-CD22
- •33.3 Other Therapeutic Perspectives
- •33.3.1 Inhibition of Other Cytokines and Chemokines
- •33.3.3 Gene Therapy
- •33.4 Conclusion
- •References
- •34.1 Introduction
- •34.5 Conclusion
- •References
- •Index
9 Autoantibodies and Autoantigens in Sjögren’s Syndrome |
123 |
|
|
modiÞed self-proteins could act as means to induce autoimmunity [166]. After the modiÞed self-proteins are taken up, digested, and processed in antigen-presenting cells (APCs), potentially self-reactive T and B cells can recognize them, resulting in the breaking of tolerance. One explanation for the mechanisms of loss of tolerance to unmodiÞed proteins following immune response to cryptic epitope is through a process called epitope spreading in part contributed by intermolecularÐintrastructural help [80]. The immune response may spread to unmodiÞed self-proteins and thus generating an autoimmune reaction [166]. The most frequently observed posttranslational modiÞcations include glycosylation, phosphorylation, acetylation, citrullination, and cleavage by apoptosis [5, 149, 167Ð169]. Several studies have shown that posttranslational modiÞcations can affect autoantibodies binding onto different autoantigens in various systemic autoimmune diseases [5, 149, 167Ð169]. Interests in Ro60 epitope (aa 169Ð 190) have been renewed recently, as McClain et al. demonstrated that this sequence could be involved, through molecular mimicry mechanisms with viral proteins, in the initiation of the autoimmune response [81]. They also showed that puriÞed antibodies against the epitope crossreacted with the peptide aa 58Ð72 sequence of the latent viral protein EpsteinÐBarr virus nuclear antigen-1 (EBNA-1). Phosphorylation of the linear B-cell epitope of SS-B/La (aa 349Ð368) enhances autoantibody binding and its relative avidity [59]. Although susceptibility to efÞcient cleavage by a caspase is a frequent feature of several SS autoantigens, it is not a universal feature of all the autoantigens. For example, caspasemediated proteolytic cleavage SS-A/Ro has not been observed [170]. Thus Rosen and co-workers have speculated alternative mechanisms such as cleavage by granzyme B, which is another effector protease especially in cell killing mediated by CD8+ cytotoxic T lymphocytes and natural killer cells [5]. Furthermore, it is known that apoptosis also can mediate not only proteolytic cleavage but also citrullination or oxidation [171]. For example, oxidized low-density lipoproteins have been found on apoptotic cells, and mice immunized
with apoptotic cells develop high titers of autoantibodies to various oxidized epitopes, whereas mice immunized with viable or necrotic cell do not [172]. These data indicate that the posttranslationally modiÞed self-antigens found on apoptotic cell are ÒneoantigensÓ capable of eliciting an immune response.
9.3.3Establishment Phase: Autoreactive T and B Lymphocytes Dysregulation and Aberrant Cytokines Production
The production and persistence of autoantibodies in autoimmune conditions may be caused by immune dysregulation with autoreactive T- lymphocyte and B-lymphocyte hyperactivation and aberrant cytokines production. InÞltrating lymphocytes and dendritic cells in affected tissues interact with salivary gland epithelial cells and contribute to the perpetuation and progression of the disease. In this context, dysregulation of cytokines production (e.g., Th1/Th2 imbalance, elevated BAFF production) and chronic B-cell hyperactivity are consistent and prominent immunoregulatory abnormalities in SS [2, 173Ð176]. Recent studies have demonstrated the B-cell hyperactivity in the inßamed tissues, especially in SS patients with detectable ectopic GClike structures [177]. Similar ectopic lymphoid structures have also been described in the target tissues of several other autoimmune conditions that are accompanied by B-cell disturbance such as RA [178, 179], SLE [178, 180], and chronic autoimmune thyroiditis [181, 182]. Delineation of common and diverse mechanisms of SS may underlie the B-cell disturbances, and the development of ectopic GC-like structures in SS entities should be important for our understanding of their immunopathogenesis.
Chronic focal periductal lymphocytic sialadenitis is a hallmark of SS and it is generally thought to be a stepwise process [2, 173, 174]. This process may include (1) a sequence of scattered tiny perivascular lymphoid inÞltrates,
(2) subsequent development of the typical focal periductal lymphoid sialadenitis/formation of
124 |
K. Nozawa et al. |
|
|
ectopic GC-like structures, and (3) eventually the destruction and replacement of the affected glandular tissue [177]. In this process, cytokine and/or autoantibody-mediated endocrine glandular tissue dysfunction may occur [106, 183]. These ectopic GC-like structures of the inßamed tissues bear a histological resemblance to the native GCs that are physiologically generated from primary B-cell follicles of secondary lymphoid organs during T-cell-dependent immune response. The ectopic GC-like structures contain T and B cells aggregate with proliferating lymphocytes, a network of follicular dendritic cells, and activated endothelial cells with the morphology of high endothelial venules [163, 179, 180, 184, 185]. Hanson et al. have explained abnormal B-cell differentiation pathways resulting in autoantibody production from the ectopic lymphoid tissues by ÒnicheÓ theory [177]. The ectopic GCs represent a niche where B cells, which are recruited by chemokines into the microenvironment of chronically inßamed tissues, may escape from peripheral check points against autoreactivity and are abnormally stimulated. B cells may proliferate and incompletely differentiate via T-cell-dependent or independent pathway into memory B cells and plasma cells, resulting in autoantibody production. Furthermore, the autoreactive B cells may be additionally stimulated by cytokines such as BAFF.
9.3.4Establishment Phase: Intermolecular–Intrastructural Help
Autoantigens are usually macromolecular complexes such as SS-A/Ro and SS-B/La, and linkages of autoimmune response among the components of the complex are often observed in patients with SS and other systemic autoimmune diseases [186, 187]. For instance, anti-Sm antibodies always occur with anti-U1RNP, and anti-SS-B/La is also associated with antibodies against SS-A/Ro and the Y5 small RNA molecule [188Ð190]. This phenomenon was also observed in autoantibodies to PCNA [191]. Such
linked sets of autoantibodies, reacting with multiple components of the same macromolecular complex, may be the products of intermolecularÐ intrastructural help, which plays a key role in the immune system [192]. The importance of intermolecularÐintrastructural help in the progression of autoimmunity is also supported by peptide immunization studies in SS-A/Ro and SS-B/La antigenÐantibody systems in which mice immunized with recombinant murine SS- B/La develop not only anti-SS-B/La antibodies but also anti-SS-A/Ro antibodies [74, 76]; conversely, immunization with SS-A/Ro causes the production of both anti-SS-B/La and anti-SS- A/Ro antibodies [74, 76]. Gordon et al. have also reported similar results in which sera from mice immunized by Ro52 and Ro60 showed reactivity against the fragment of SS-B/La protein [73]. The explanation for these observations is that T cells speciÞc for the immunized antigen can provide help to B cells carrying receptor for other components such as in the case of SS-A/Ro-SS- B/La complex. Alternatively, or in addition, the spread of autoimmunity to other proteins within a macromolecular complex may come from distinct products of the antigen processing by APC [193, 194]. This suggests that activated autoreactive B cells (or professional APC) can prime autoreactive T cells.
9.3.5 Effector Phase
Although tissue destruction mediated by autoreactive cytotoxic T cells and aberrant cytokines such as TNF-α is considered as major factor of the tissue damage of SS, antibody-mediated tissue destruction is also believed to play an important role in the process. Clancy et al. recently reported novel effector mechanisms of tissue destruction mediated by autoantibodies [67]. They demonstrated that anti-SS-A/Ro and anti-SS-B/La antibodies bound to apoptotic cardiomyocytes caused an impaired clearance of the apoptotic cells. Blocking physiologic apoptotic cell clearance by autoantibody binding of apoptotic cells would be expected to skew the pool of IgG autoantibodyÐapoptotic
